Technology evaluation: Kahalalide F, PharmaMar.
Kahalalide F is a depsipeptide under development by PharmaMar as a potential treatment for solid tumors. It is currently undergoing phase II clinical trials.
Hamann
Mark T
MT
University of Mississippi, The School of Pharmacy and Department of Chemistry and Biochemistry, PO Box 1848, MS 38677, USA. mthamann@olemiss.edu
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D047630:Depsipeptides / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D004341:Drug Evaluation / Q000379:methods; D015507:Drugs, Investigational / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use
D000970:Antineoplastic Agents; D047630:Depsipeptides; D015507:Drugs, Investigational; D007155:Immunologic Factors; C097897:kahalalide F